Overview

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

Status:
Recruiting

Trial end date:
2024-12-05

Target enrollment:

Participant gender:

Summary

This study is being done to look at how effective the drug, atezolizumab, with or without the drug bevacizumab, is for people with inoperable liver cancer or non-small lung cancer that has spread to the liver. This will be done by looking at the duration of time from starting the study drug(s) until the cancer worsens in study participants. This study will collect blood and tumor tissue samples from participants to look at changes to their tumor(s) before and after receiving atezolizumab and/or bevacizumab.

Phase:

Phase 2

Details

Lead Sponsor:

University Health Network, Toronto

Collaborator:

Hoffmann-La Roche

Treatments:

Atezolizumab
Bevacizumab